A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism.
A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism.
Single-dose CBD increased caloric intake by 193 kcal at lunch in healthy adults without affecting glucose or lipid metabolism.
This controlled trial demonstrates that acute CBD administration can stimulate appetite in healthy individuals, contradicting common assumptions about CBD’s appetite-suppressing effects. The study design allows for causal inference about CBD’s immediate impact on food intake behavior.
This finding challenges widespread beliefs that CBD suppresses appetite and suggests clinicians should counsel patients that CBD may increase caloric intake. For patients using CBD for other indications, this appetite-stimulating effect represents a potential side effect requiring monitoring.
| Study Type | Randomized Controlled Trial |
| Population | 15 healthy adults (4 females) |
| Intervention | 298 mg CBD single dose |
| Comparator | Placebo |
| Primary Outcome | Ad libitum energy intake at lunch 180 minutes post-dose |
| Key Finding | 193 kcal greater intake with CBD vs placebo (979 vs 786 kcal, p=0.003) |
| Journal | Appetite |
| Year | 2024 |
A single 298 mg dose of CBD increased voluntary food intake by approximately 200 calories without affecting metabolic parameters in healthy adults. This appetite-stimulating effect occurs acutely and should be considered when prescribing CBD.
The study cannot establish chronic effects of CBD on appetite, weight gain, or metabolic health with repeated dosing. It does not demonstrate effects in patients with medical conditions, appetite disorders, or those taking other medications that might interact with CBD.
The small sample size (n=15) with only 4 females limits generalizability. The single-dose design may not reflect real-world CBD use patterns, and individual variability in CBD metabolism could affect responses significantly.
CBD may increase caloric intake acutely in healthy individuals, contrary to popular belief. This finding requires replication in larger, more diverse populations before making broad clinical recommendations about CBD and appetite regulation.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Does CBD increase appetite and food intake in healthy adults?
Yes, a single 298 mg dose of CBD significantly increased energy intake by 193 kcal (about 25% more) at an ad libitum lunch compared to placebo in healthy adults. This appetite-stimulating effect occurred approximately 3 hours after CBD administration, suggesting CBD may have orexigenic properties in humans.
Will CBD affect my blood sugar or cholesterol levels after meals?
Based on this study, CBD does not appear to affect postprandial glucose or lipid metabolism following a mixed-macronutrient meal. Despite the increased food intake, participants showed no significant changes in blood-based energy substrates or metabolic markers compared to placebo.
How much CBD was used in this study and when did effects occur?
Participants received a single 298 mg dose of CBD, which is considered a relatively high dose. The appetite-stimulating effects were measured 180 minutes (3 hours) after CBD ingestion, indicating the effects may take several hours to manifest.
Are these appetite effects of CBD clinically relevant for patients?
The 193 kcal increase in food intake represents a clinically meaningful change that could be relevant for patients with appetite loss or wasting conditions. However, this study only included 15 healthy adults (mostly males), so results may not generalize to patient populations or women.
Could CBD be useful for treating appetite disorders or weight loss?
While this study suggests CBD may stimulate appetite, it was conducted in healthy individuals rather than patients with appetite disorders. Further research is needed in clinical populations with conditions like cancer cachexia, anorexia, or involuntary weight loss to determine therapeutic potential.
